Fidelity Investments’s Aratana Therapeutics, Inc. PETX Stock Holding History

Fidelity Investments’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-360,000	Closed	-$3.05M	–	2800
2015 Q3	$3.05M	Buy	360,000 +60,000	+20%	+$1.02M	﹤0.01%	2313
2015 Q2	$4.54M	Buy	+300,000	New	+$4.33M	﹤0.01%	2269
2014 Q2	–	Sell	-375,000	Closed	-$6.26M	–	2830
2014 Q1	$6.26M	Sell	375,000 -650,000	-63%	-$13M	﹤0.01%	2158
2013 Q4	$18.9M	Buy	1,025,000 +169,450	+20%	+$3.44M	﹤0.01%	1734
2013 Q3	$14M	Buy	+855,550	New	+$8.99M	﹤0.01%	1826

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity Investments's PETX Position: Q4 2015 in Review

Fidelity Investments sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2015, closing a stake of 360,000 shares — an estimated $3.05M sold.

Fidelity Investments first reported a position in PETX in Q3 2013 and held it in 5 quarters. The position peaked at $18.9M in Q4 2013. 98 funds tracked by Wall St. Rank hold PETX as of Q4 2015.

Fidelity Investments reported no remaining Aratana Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
Fidelity Investments sold 360,000 Aratana Therapeutics, Inc. shares in Q4 2015, an estimated $3.05M.
Fidelity Investments first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 5 quarters.
Fidelity Investments's Aratana Therapeutics, Inc. position peaked at $18.9M in Q4 2013.
98 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2015.

Based on Fidelity Investments's 13F filing for Q4 2015, filed 12 Feb 2016.